Amy Heath

1.5k total citations
17 papers, 1.2k citations indexed

About

Amy Heath is a scholar working on Surgery, Gastroenterology and Rheumatology. According to data from OpenAlex, Amy Heath has authored 17 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Surgery, 8 papers in Gastroenterology and 3 papers in Rheumatology. Recurrent topics in Amy Heath's work include Gastrointestinal motility and disorders (7 papers), Helicobacter pylori-related gastroenterology studies (5 papers) and Opioid Use Disorder Treatment (3 papers). Amy Heath is often cited by papers focused on Gastrointestinal motility and disorders (7 papers), Helicobacter pylori-related gastroenterology studies (5 papers) and Opioid Use Disorder Treatment (3 papers). Amy Heath collaborates with scholars based in United States, United Kingdom and Netherlands. Amy Heath's co-authors include George E. Dukes, Allison R. Northcutt, Allen W. Mangel, T. Perschy, William Y. Chey, Vanessa Z. Ameen, Eric G. Carter, Margaret H. Collins, Amal Assa’ad and Héctor Ortega and has published in prestigious journals such as Gastroenterology, PLoS ONE and The American Journal of Gastroenterology.

In The Last Decade

Amy Heath

17 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Amy Heath United States 11 595 595 410 284 222 17 1.2k
Hamish Philpott Australia 16 550 0.9× 291 0.5× 319 0.8× 122 0.4× 85 0.4× 50 894
Pertti Aro Sweden 22 2.1k 3.6× 2.0k 3.4× 266 0.6× 191 0.7× 110 0.5× 37 2.6k
Tom Storskrubb Sweden 18 1.9k 3.2× 1.7k 2.9× 232 0.6× 129 0.5× 106 0.5× 26 2.3k
Frédérique Maurel France 13 127 0.2× 162 0.3× 155 0.4× 93 0.3× 94 0.4× 32 624
E. Bolling‐Sternevald Sweden 20 2.1k 3.5× 1.8k 3.0× 197 0.5× 113 0.4× 79 0.4× 29 2.4k
Charles Steadman Australia 17 360 0.6× 340 0.6× 42 0.1× 149 0.5× 21 0.1× 25 782
R. Gillberg Sweden 17 442 0.7× 633 1.1× 42 0.1× 88 0.3× 80 0.4× 28 1.1k
Alex Fich Israel 16 297 0.5× 284 0.5× 26 0.1× 65 0.2× 59 0.3× 32 618
Tisha Lunsford United States 12 302 0.5× 154 0.3× 158 0.4× 90 0.3× 64 0.3× 27 617
Magnus Halland United States 18 454 0.8× 476 0.8× 69 0.2× 117 0.4× 12 0.1× 52 777

Countries citing papers authored by Amy Heath

Since Specialization
Citations

This map shows the geographic impact of Amy Heath's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Amy Heath with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Amy Heath more than expected).

Fields of papers citing papers by Amy Heath

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Amy Heath. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Amy Heath. The network helps show where Amy Heath may publish in the future.

Co-authorship network of co-authors of Amy Heath

This figure shows the co-authorship network connecting the top 25 collaborators of Amy Heath. A scholar is included among the top collaborators of Amy Heath based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Amy Heath. Amy Heath is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Mariani, John J., et al.. (2023). Open‐label investigation of rapid initiation of extended‐release buprenorphine in patients using fentanyl and fentanyl analogs. American Journal on Addictions. 33(1). 8–14. 8 indexed citations
2.
Dobbins, Robert L., Amy Heath, Monique van Velzen, et al.. (2022). Effect of sustained high buprenorphine plasma concentrations on fentanyl-induced respiratory depression: A placebo-controlled crossover study in healthy volunteers and opioid-tolerant patients. PLoS ONE. 17(1). e0256752–e0256752. 25 indexed citations
3.
Shinde, Sunita N., et al.. (2022). Open-label, rapid initiation pilot study for extended-release buprenorphine subcutaneous injection. The American Journal of Drug and Alcohol Abuse. 49(1). 43–52. 8 indexed citations
4.
Csernansky, John G., Robert A. Leadbetter, Anne C. Andorn, et al.. (2021). PANSS Individual Item and Marder Dimension Analyses From a Pivotal Trial of RBP-7000 (Monthly Extended-Release Risperidone) in Schizophrenia Patients. The Journal of Clinical Psychiatry. 82(5). 8 indexed citations
5.
Wallace, Daniel J., Ellen M. Ginzler, Joan T. Merrill, et al.. (2019). Safety and Efficacy of Belimumab Plus Standard Therapy for Up to Thirteen Years in Patients With Systemic Lupus Erythematosus. Arthritis & Rheumatology. 71(7). 1125–1134. 84 indexed citations
6.
Vollenhoven, Ronald van, Sandra Navarra, Roger A. Levy, et al.. (2019). Long-term safety and limited organ damage in patients with systemic lupus erythematosus treated with belimumab: a Phase III study extension. Lara D. Veeken. 59(2). 281–291. 64 indexed citations
7.
Assa’ad, Amal, Sandeep K. Gupta, Margaret H. Collins, et al.. (2011). An Antibody Against IL-5 Reduces Numbers of Esophageal Intraepithelial Eosinophils in Children With Eosinophilic Esophagitis. Gastroenterology. 141(5). 1593–1604. 325 indexed citations
8.
Krause, Richard A., Vanessa Z. Ameen, Susan Gordon, et al.. (2007). A Randomized, Double-Blind, Placebo-Controlled Study to Assess Efficacy and Safety of 0.5 mg and 1 mg Alosetron in Women With Severe Diarrhea-predominant IBS. The American Journal of Gastroenterology. 102(8). 1709–1719. 96 indexed citations
9.
Chey, William D., William Y. Chey, Amy Heath, et al.. (2004). Long-Term Safety and Efficacy of Alosetron in Women with Severe Diarrhea-Predominant Irritable Bowel Syndrome. The American Journal of Gastroenterology. 99(11). 2195–2203. 116 indexed citations
10.
Lembo, Anthony, et al.. (2004). Effect of alosetron on bowel urgency and global symptoms in women with severe, diarrhea-predominant irritable bowel syndrome: Analysis of two controlled trials. Clinical Gastroenterology and Hepatology. 2(8). 675–682. 56 indexed citations
11.
Ameen, Vanessa Z., Susan Gordon, Amy Heath, & Eric G. Carter. (2004). SYMPTOM SEVERITY IN WOMEN WITH DIARRHEA-PREDOMINANT IBS (D-IBS). The American Journal of Gastroenterology. 99. S275–S275. 1 indexed citations
12.
Camilleri, Michael, William Y. Chey, Emeran A. Mayer, et al.. (2001). A Randomized Controlled Clinical Trial of the Serotonin Type 3 Receptor Antagonist Alosetron in Women With Diarrhea-Predominant Irritable Bowel Syndrome. Archives of Internal Medicine. 161(14). 1733–1733. 236 indexed citations
13.
Northcutt, Allison R., Allen W. Mangel, Lynne Hamm, et al.. (2001). Persistent placebo response during a year-long controlled trial of IBS treatment. Gastroenterology. 120(5). A640–A640. 6 indexed citations
14.
Hamm, Lynne, et al.. (1999). Additional Investigations Fail to Alter The Diagnosis of Irritable Bowel Syndrome in Subjects Fulfilling The Rome Criteria. The American Journal of Gastroenterology. 94(5). 1279–1282. 98 indexed citations
15.
Lanza, Frank L., et al.. (1998). Ranitidine Bismuth Citrate Plus Clarithromycin: A Dual Therapy Regimen for Patients with Duodenal Ulcer. Helicobacter. 3(3). 212–221. 10 indexed citations
16.
Hamm, Lynne, et al.. (1998). Utility of screening tests in irritable bowel syndrome. Gastroenterology. 114. A760–A760. 4 indexed citations
17.
Hamm, Lynne, R. S. B. Ehsanullah, Amy Heath, et al.. (1997). Use of a novel electronic data collection system in multicenter studies of irritable bowel syndrome. Alimentary Pharmacology & Therapeutics. 11(6). 1073–1076. 31 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Hamish Philpott Breakdown of academic impact, for papers by Pertti Aro Breakdown of academic impact, for papers by Tom Storskrubb Breakdown of academic impact, for papers by Frédérique Maurel Breakdown of academic impact, for papers by E. Bolling‐Sternevald Breakdown of academic impact, for papers by Charles Steadman Breakdown of academic impact, for papers by R. Gillberg Breakdown of academic impact, for papers by Alex Fich Breakdown of academic impact, for papers by Tisha Lunsford Breakdown of academic impact, for papers by Magnus Halland
Rankless by CCL
2026